Chronic Myeloid Leukemia clinical trials

Explore recruiting chronic myeloid leukemia clinical trials.

Recruiting chronic myeloid leukemia studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Chronic Myeloid Leukemia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Prospective Phase II Clinical Trial Evaluating the Efficacy and the Safety of Tyrosine Kinase Inhibitors Withdrawal After a Previous Two-step Dose Reduction in Patients With Chronic Myeloid Leukemia in Deep Molecular Remission

Czechia

Therapeutic exploratory (Phase II) EU CTIS Study details

Efficacy of asciminib in chronic phase CML patients with T315l mutations

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Safety and efficacy of treatment combination with ponatinib and asciminib in chronic myeloid leukemia patients resistant to ponatinib and/or asciminib

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase I/II study of Bosutinib in pediatric patients with newly diagnosed chronic phase or resistant/intolerant Ph+ Chronic Myeloid Leukemia, study ITCC-054/COG AAML1921

France, Germany, Spain, Netherlands, Italy

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Frontline Asciminib combination in chronic phase CML

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

With Ponatinib on the track for treatment-free-remission in chronic myeloid leukemia

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Chronic Myeloid Leukemia trials by city

Chronic Myeloid Leukemia clinical trials

Recruiting chronic myeloid leukemia studies right now

Q702 for the Treatment of Patients With Hematologic Malignancies

A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.

Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML.

3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases

Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant

Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies

Phase I Trial of Vididencel in CML-CP Patients With MRD Under TKI Treatment

Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

Also recruiting in Europe

A Prospective Phase II Clinical Trial Evaluating the Efficacy and the Safety of Tyrosine Kinase Inhibitors Withdrawal After a Previous Two-step Dose Reduction in Patients With Chronic Myeloid Leukemia in Deep Molecular Remission

Efficacy of asciminib in chronic phase CML patients with T315l mutations

Safety and efficacy of treatment combination with ponatinib and asciminib in chronic myeloid leukemia patients resistant to ponatinib and/or asciminib

A Phase I/II study of Bosutinib in pediatric patients with newly diagnosed chronic phase or resistant/intolerant Ph+ Chronic Myeloid Leukemia, study ITCC-054/COG AAML1921

Frontline Asciminib combination in chronic phase CML

With Ponatinib on the track for treatment-free-remission in chronic myeloid leukemia

Chronic Myeloid Leukemia trials by city

Other conditions